Nemaura Medical (NASDAQ: NMRD), a medical technology company focused on developing and commercializing noninvasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, today announced the beta launch of MiBoKo, a new metabolic health program utilizing a noninvasive glucose sensor along with an AI mobile application. According to the update, Nemaura’s Chief Executive Officer Dr. Faz Chowdhury will discuss MiBoKo in more detail during his corporate presentation scheduled for today, Sept. 29, 2021, at 11:10 a.m. ET during the Benzinga Healthcare Small Cap Conference. Investors can access the presentation by registering for the conference at https://ibn.fm/tbmt0. “A person’s response to sugar intake can influence a number of factors from appetite and body weight to sleep patterns, energy levels and even mood, not to mention also being a considerable factor in chronic diseases like diabetes, heart disease and dementia,” explains Dr. Chowdhury. “With MiBoKo, we are able to extend our proprietary noninvasive device and sensor technology and interactive lifestyle and AI coaching programs beyond the traditional diabetes market and into an adjacent, yet separate, market application of metabolic health. At Nemaura, we continue to look for the intersection of patient comfort and convenience through advanced and unique technology that addresses significant healthcare needs for large patient populations. We believe that MiBoKo offers insights into metabolic health in a user-friendly way unlike any other program on the market.”
To view the full press release, visit https://ibn.fm/lHuRL
About Nemaura Medical Inc.
Nemaura Medical is a medical technology company developing and commercializing noninvasive wearable diagnostic devices. The company is currently commercializing sugarBEAT(R) and proBEAT(TM). sugarBEAT, a CE mark approved Class IIb medical device, is a non-invasive and flexible continuous glucose monitor (“CGM”) providing actionable insights derived from real-time glucose measurements and daily glucose trend data, which may help people with diabetes and pre-diabetes to better manage, reverse and prevent the onset of diabetes. Nemaura has submitted a PMA (Premarket Approval Application) for sugarBEAT to the U.S. FDA. proBEAT combines non-invasive glucose data processed using artificial intelligence and a digital health care subscription service and has been launched in the U.S. as a general wellness product as part of its BEAT(R) diabetes program. The company sits at the intersection of the global type 2 diabetes market that is expected to reach nearly $59 billion by 2025, the $50+ billion pre-diabetic market, and the wearable health-tech sector for weight loss and wellness applications that is estimated to reach $60 billion by 2023. For more information, please visit www.NemauraMedical.com.
NOTE TO INVESTORS: The latest news and updates relating to NMRD are available in the company’s newsroom at https://ibn.fm/NMRD
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.InvestorWire.com
InvestorWire is part of the InvestorBrandNetwork.